DarioHealth (NASDAQ:DRIO) Shares Pass Above 50 Day Moving Average – Here’s Why

DarioHealth Corp. (NASDAQ:DRIO)’s stock price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $7.42 and traded as high as $7.49. DarioHealth shares last traded at $7.22, with a volume of 2,316 shares traded.

Analysts Set New Price Targets

DRIO has been the topic of a number of recent analyst reports. TD Cowen restated a “hold” rating and set a $11.00 price objective on shares of DarioHealth in a research note on Wednesday, May 13th. Stifel Nicolaus reissued a “buy” rating and set a $10.00 target price on shares of DarioHealth in a research note on Thursday, May 14th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $10.50.

DarioHealth Price Performance

The firm has a market capitalization of $52.78 million, a P/E ratio of -0.81 and a beta of 1.09. The business’s fifty day moving average is $7.41 and its 200 day moving average is $8.98. The company has a current ratio of 3.07, a quick ratio of 2.62 and a debt-to-equity ratio of 0.50.

Hedge Funds Weigh In On DarioHealth

Institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd raised its holdings in DarioHealth by 229.0% during the 2nd quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock worth $42,000 after buying an additional 43,513 shares during the period. Geode Capital Management LLC boosted its stake in DarioHealth by 167.9% in the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock worth $564,000 after purchasing an additional 31,063 shares during the period. Finally, Kestra Advisory Services LLC purchased a new stake in shares of DarioHealth in the fourth quarter valued at $35,000. Hedge funds and other institutional investors own 33.39% of the company’s stock.

About DarioHealth

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.